权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

PQ#12; Targeting Nampt-mediated NAD+ metabolism in chemobrain

质子Q

基本信息

批准号：
10688638
负责人：
Mi-Hyeon Jang
金额：
$ 13.6万
依托单位：
RUTGERS BIOMEDICAL AND HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-08 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10688638
关键词：
Adult Affect Anabolism Antineoplastic Agents Behavioral Brain Brain region Cancer Survivor Cell division Cell physiology Cisplatin Clinical Trials Coenzymes Cognitive Cognitive deficits Confocal Microscopy DNA Repair Data Dendrites Dendritic Spines Development Enhancers Ensure Enzymes Functional disorder Gliosis Glycolysis Goals Hippocampus (Brain)Impaired cognition Impairment Laboratories Learning Malignant Neoplasms Malignant neoplasm of ovary Mediating Medical Memory Memory impairment Metabolic Metabolic Pathway Metabolism Molecular Morphology Mus Neuronal Dysfunction Neurons Niacinamide Nicotinamide Mononucleotide Nicotinamide adenine dinucleotide Pathway interactions Patients Pharmaceutical Preparations Pharmacology Platinum Play Process Quality of life Role Safety Supplementation Testing Therapeutic Transferase Translational Research United States Work age related neurodegeneration aged base behavior test cancer therapy chemobrain chemotherapy clinically relevant cognitive function cohort comorbidity drug development effective therapy enzyme activity healthspan improved insight mouse genetics mouse model myelination neurogenesis neurotoxicity novel novel therapeutic intervention older patient overexpression patient derived xenograft model prevent side effect stem therapeutic target therapeutically effective

项目摘要

PROJECT SUMMARY Chemotherapy-induced cognitive dysfunction (referred to as chemobrain) negatively impacts cancer survivors and has emerged as a significant medical problem. To date, no effective treatment exists due to the limited understanding of the mechanisms that drive chemotherapy-induced cognitive impairments. To provide effective therapeutic strategies for this emergent medical problem, this application aims to answer Provocative Question #12: What are the molecular and cellular mechanisms that underlie the development of cancer therapy-induced severe adverse sequelae? While the underlying molecular pathways vulnerable to chemotherapy-induced neurotoxicity are not well understood, recent results from our laboratory indicate the Nampt-mediated NAD+ pathway is a promising therapeutic target for chemobrain. Using the platinum-based chemotherapy compound cisplatin, we demonstrate its efficacy in suppressing the nicotinamide phosphoribosyl transferase (Nampt)-mediated NAD+ metabolic pathway. Cisplatin-mediated suppression of Nampt-NAD+ metabolism leads to neurogenic dysfunction of the adult mouse hippocampus and memory impairments. Remarkably, we found that by increasing NAD+ levels via administration of the NAD+ precursor nicotinamide mononucleotide (NMN), we can effectively reverse cisplatin-induced deficits in neuronal dendrite morphology and memory function, thus emphasizing the therapeutic potential of NAD+ metabolism in amelioration of chemobrain. Based on these observations, our central hypothesis is that increasing Nampt or NAD+ levels prevent cisplatin-induced impairments in neuronal and cognitive function. Our findings represent a novel therapeutic strategy for chemobrain. To test this novel hypothesis, Aim 1 will determine whether increasing NAD+ levels through NMN supplementation can improve cisplatin-induced deficits in neuronal and cognitive function in both young and aged mice. In addition, our translational proposal will ensure the safety of NMN, as we will determine if NMN has a detrimental impact on anti-neoplastic activity of cisplatin using patient-derived xenograft (PDX) mouse models. Subsequently, Aim 2 will elucidate if genetically increasing Nampt levels can prevent impairments in neuronal morphology and cognitive function. We will also evaluate if P7C3, a Nampt enzyme activity enhancer, can improve cisplatin-induced chemobrain in young and aged mice. Our proposed work will provide critical pathophysiological mechanisms and improve our understanding of the Nampt-mediated NAD+ metabolic pathway in order to improve chemotherapy-induced cognitive dysfunction. Ultimately, the findings will provide a framework by which safe and effective therapeutic strategies may be utilized in patients undergoing cancer treatment so as to minimize or reverse neuronal and memory dysfunction.

项目总结